Chunghwa Chemical Synthesis & Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Chunghwa Chemical Synthesis & Biotech has a total shareholder equity of NT$3.3B and total debt of NT$1,000.0M, which brings its debt-to-equity ratio to 30%. Its total assets and total liabilities are NT$4.9B and NT$1.5B respectively. Chunghwa Chemical Synthesis & Biotech's EBIT is NT$86.3M making its interest coverage ratio 4.8. It has cash and short-term investments of NT$196.8M.
Key information
30.0%
Debt to equity ratio
NT$1.00b
Debt
| Interest coverage ratio | 4.8x |
| Cash | NT$196.80m |
| Equity | NT$3.34b |
| Total liabilities | NT$1.53b |
| Total assets | NT$4.87b |
Recent financial health updates
Recent updates
Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 22
Chunghwa Chemical Synthesis & Biotech (TWSE:1762) Has A Somewhat Strained Balance Sheet
Nov 14Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry
Aug 09Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80
Jul 12Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
Apr 01Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 04What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend
Jan 28Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?
Jan 02The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It
Dec 06Financial Position Analysis
Short Term Liabilities: 1762's short term assets (NT$1.5B) exceed its short term liabilities (NT$549.3M).
Long Term Liabilities: 1762's short term assets (NT$1.5B) exceed its long term liabilities (NT$979.4M).
Debt to Equity History and Analysis
Debt Level: 1762's net debt to equity ratio (24.1%) is considered satisfactory.
Reducing Debt: 1762's debt to equity ratio has reduced from 45.9% to 30% over the past 5 years.
Debt Coverage: 1762's debt is well covered by operating cash flow (30.7%).
Interest Coverage: 1762's interest payments on its debt are well covered by EBIT (4.8x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 03:34 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chunghwa Chemical Synthesis & Biotech Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Ryan Liu | IBTS Investment Consulting Co., Ltd. |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |